AKBA
Akebia Therapeutics, Inc.
0.8962$
-2.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 42.8% | 33.2% | 8.3% | 19.0% | 37.8% | 43.8% | 13.3% | 15.9% | 16.5% | 21.2% | 23.6% | 21.2% | 20.5% | |
| 57.2% | 66.8% | 91.7% | 81.0% | 62.2% | 56.2% | 86.7% | 84.1% | 83.5% | 78.8% | 76.4% | 78.8% | 79.5% | |
| 31.7% | 17.6% | 29.8% | 17.5% | 22.7% | 25.3% | 17.0% | 17.6% | 24.9% | 46.2% | 27.7% | 28.6% | 32.0% | |
| 54.0% | 1.5% | 78.0% | 61.7% | 70.8% | 49.6% | 44.9% | 42.5% | 49.5% | 45.3% | 56.8% | 57.3% | 51.9% | |
| 88.2% | 64.3% | 137.5% | 101.0% | 95.6% | 87.0% | 63.1% | 61.6% | 75.9% | 93.6% | 85.2% | 91.7% | 86.4% | |
| -31.0% | 2.4% | -45.8% | -20.0% | -33.4% | -30.8% | 23.6% | 22.6% | 7.6% | -14.8% | -8.8% | -12.9% | -6.9% | |
| 3.4% | 2.5% | 7.7% | 4.9% | 17.8% | 14.8% | 13.6% | 10.9% | 8.1% | 8.4% | 8.8% | 6.3% | 7.9% | |
| -34.5% | 1.1% | -55.2% | -19.7% | -53.5% | -49.0% | 10.7% | 0.4% | 2.0% | -19.5% | -16.7% | -18.0% | -12.7% | |
| 3.3% | 0.0% | 28.6% | – | – | – | – | – | 1.0% | 1.8% | 0.2% | 0.1% | 0.8% | |
| -34.5% | 1.1% | -55.2% | -19.7% | -53.5% | -49.0% | 10.7% | 0.4% | 0.9% | -21.2% | -16.9% | -18.1% | -13.5% | |
| -8.7% | 20.4% | -15.1% | 2.7% | -10.7% | -14.2% | 24.8% | 11.8% | 10.6% | -10.6% | -24.8% | -9.9% | -8.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.